Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Palatin Technologies, Inc.
CRANBURY, N.J., July 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes composition of matter claims on broad families of melanocortin receptor-1 specific peptides with potential utility for treatment of inflammatory diseases and disorders.
The melanocortin-1 receptor mediates inflammatory responses, and melanocortin-1 receptor agonist peptides have potential application for indications such as inflammatory bowel disease, uveitis, nephritis and rheumatoid arthritis. Palatin has conducted preliminary preclinical studies in both inflammatory bowel disease and uveitis, and is advancing additional confirmatory preclinical studies in these indications prior to initiating human clinical trials. Palatin is conducting preclinical toxicology and other studies preparatory to filing an Investigational New Drug (IND) application with the Food and Drug Administration (FDA), and anticipates having one or more pre-IND meetings with the FDA prior to filing an IND this year.
"We believe that our melanocortin-1 receptor peptide agonists, which are both highly selective and specific, represent a new paradigm for treatment of inflammatory diseases and disorders," stated Carl Spana, Ph.D., President and CEO of Palatin. "Securing strong patent protection is a key component of our development program."
The peptides claimed in the '422 application are highly specific for the melanocortin-1 receptor, with a number of peptides having sub-nanomolar affinity binding and EC50 functional values. Many of the peptides are also highly selective for the melanocortin-1 receptor, with greater than one thousand times the affinity for the melanocortin-1 receptor than for the melanocortin-4 or melanocortin-3 receptors.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. When issued, the patent twenty-year term would not expire until November 2030 at the earliest. The Notice of Allowance for the '422 application has been posted on the USPTO public PAIR website.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about potential clinical utility of melanocortin receptor-1 agonist peptides, whether the subject patent will issue or adequately protect against competition, the future status of pending and planned patent applications, potential clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), regulatory plans, development programs, proposed indications for melanocortin receptor-4 agonist peptide product candidates and market potential for melanocortin receptor-4 agonist peptide product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of nonclinical, preclinical and toxicology studies, result of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.
©2012 PR Newswire. All Rights Reserved.